Dr. David Perlmutter
speaker
551 appearances
1 recordings
1 series
first heard Jul 2026
last heard 9 Jul
Dr. David Perlmutter’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.
Appearances
Who knows?
So I think there's value in that.
And it may be that oral uh semaglutide doesn't make it through the blood brain barrier.
It may be the semaglutide in and of itself uh is too big a molecule.
That's not what was used in the Parkinson's study.
They use lyxosenotide, which is a smaller molecule.
They use it because it's more able to cross the blood brain barrier.
But you know, we could talk about concerns.
Of full on dosage of these drugs, what that might do in the long term.
The answer is who knows?
Yeah.
When you stimulate these receptors with a thousandfold greater levels than they've ever seen, I I don't know that that's necessarily the right thing to do.
Why I would be in favor of it uh in Alzheimer's or Parkinson is because we know how the how it otherwise is going to end up, right?
Yeah, and I said it in the book.
And uh I said, uh, you know, you may be surprised to know that uh my what's my feeling about all this?
I said that if it proves that these drugs are efficacious and safe, uh I w will be full on supportive.
Yeah, I I think so.
And I do wanna add though that in the Parkinson study that about forty eight percent of the people who received the drug had significant gastrointestinal side effects.
I mean, you know, really big issues.
But I think it uh then what does it tell us?
Showing 381–400 of 551 · page 20 of 28
← Previous
Next →